The Effect of a Community-Based Exercise Program on Inflammation, Metabolic Risk, and Fitness Levels Among Persons Living with HIV/AIDS

AIDS and Behavior

Volumn 20, Issue 5, 2016, Pages 1123-1131

  Cutrono, Stacy E ^a,b   Lewis, John E ^c   Perry, Arlette ^a   Signorile, Joseph ^a   Tiozzo, Eduard ^c   Jacobs, Kevin A ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Aerobic exercise; C reactive protein; Human immunodeficiency virus; Inflammation; Metabolic risk; Resistance training

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BLOOD; BLOOD PRESSURE; EXERCISE; FEMALE; FITNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KINESIOTHERAPY; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RESISTANCE TRAINING; RISK FACTOR;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BIOMARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; EXERCISE; EXERCISE THERAPY; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PHYSICAL FITNESS; RESISTANCE TRAINING; RISK FACTORS;

EID: 84948151488     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-015-1245-1     Document Type: Article

References (49)

1. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global AIDS Epidemic. 2013.
2. Centers for Disease Control and Prevention. HIV in the United States: at a glance. http://www.cdc.gov/hiv/statistics/basics/ataglance.html#ref1. Accessed 15 Nov 2013.
3. Florida Health. Epidemiology of HIV Infection and trends in Florida reported through 2012. 2013.
4. Collaboration Antiretroviral Therapy Cohort. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96.
5. Darbyshire J. Therapeutic interventions in HIV infection—a critical view. Trop Med Int Health. 2000;5(7):A26–31.
6. Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study AIDS. 1998;12(10):1195–201.
7. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17–26.
8. Tiozzo E, Jayaweera D, Rodriguez A, et al. Short-term combined exercise training improves the health of HIV-infected patients. J AIDS HIV Res. 2013;5(3):80–9.
9. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med. 2011;5(2):171–86.
10. Leow MK, Addy CL, Mantzoros CS. Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88(5):1961–76.
11. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.
12. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–12.
13. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010;5(6):498–503.
14. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–95.
15. Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis. 2010;201(2):285–92.
16. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637–46.
17. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166(1):64–70.
18. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009;200(6):973–83.
19. O’Brien K, Nixon S, Tynan AM, Glazier R. Aerobic exercise interventions for adults living with HIV/AIDS. Cochrane Database Syst Rev. 2010. doi:10.1002/14651858.CD001796.pub3.
20. O’Brien K, Tynan AM, Nixon S, Glazier RH. Effects of progressive resistive exercise in adults living with HIV/AIDS: systematic review and meta-analysis of randomized trials. AIDS Care. 2008;20(6):631–53.
21. ACSM. ACSM’s guidelines for exercise testing and prescription. 9th ed. Baltimore: Wolters Kluwer|Lippincott Williams & Wilkins; 2009.
22. Arikawa AY, Thomas W, Schmitz KH, Kurzer MS. Sixteen weeks of exercise reduces C-reactive protein levels in young women. Med Sci Sports Exerc. 2011;43(6):1002–9.
23. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology. 2002;13(5):561–8.
24. Kohut ML, McCann DA, Russell DW, et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun. 2006;20(3):201–9.
25. Campbell PT, Campbell KL, Wener MH, et al. A yearlong exercise intervention decreases CRP among obese postmenopausal women. Med Sci Sports Exerc. 2009;41(8):1533–9.
26. Kelley GA, Kelley KS. Effects of aerobic exercise on C-reactive protein, body composition, and maximum oxygen consumption in adults: a meta-analysis of randomized controlled trials. Metabolism. 2006;55(11):1500–7.
27. 2max from a one-mile track walk, gender, age, and body weight. Med Sci Sports Exerc. 1987;19(3):253–9.
28. Maruf FA, Akinpelu AO, Salako BL. Self-reported quality of life before and after aerobic exercise training in individuals with hypertension: a randomised-controlled trial. Appl Psychol Health Well Being. 2013;5(2):209–24.
29. Program National Cholesterol Education. (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
30. United States Census Bureau. State and county QuickFacts. http://quickfacts.census.gov/qfd/states/00000.html. Accessed 18 May 2014.
31. Meredith K, Delaney J, Horgan M, Fisher E Jr, Fraser V. A survey of women with HIV about their expectations for care. AIDS Care. 1997;9(5):513–22.
32. Kelly PJ, Cordell JR. Recruitment of women into research studies: a nursing perspective. Clin Nurse Spec. 1996;10(1):25–8.
33. MacArthur RD, Levine SD, Birk TJ. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med Sci Sports Exerc. 1993;25(6):684–8.
34. Neidig JL, Smith BA, Brashers DE. Aerobic exercise training for depressive symptom management in adults living with HIV infection. J Assoc Nurses AIDS Care. 2003;14(2):30–40.
35. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005;165(18):2063–8.
36. Smith BA, Neidig JL, Nickel JT, Mitchell GL, Para MF, Fass RJ. Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS. 2001;15(6):693–701.
37. Lindegaard B, Hansen T, Hvid T, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab. 2008;93(10):3860–9.
38. Gomes Neto M, Ogalha C, Andrade AM, Brites C. A systematic review of effects of concurrent strength and endurance training on the health-related quality of life and cardiopulmonary status in patients with HIV/AIDS. Biomed Res Int. 2013;2013:319524.
39. Hand GA, Lyerly GW, Jaggers JR, Dudgeon WD. Impact of aerobic and resistance exercise on the health of HIV-infected persons. Am J Lifestyle Med. 2009;3(6):489–99.
40. DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–35.
41. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6):1056–74.
42. Borato DC, Parabocz GC, Ribas SR, et al. Changes of metabolic and inflammatory markers in HIV infection: glucose, lipids, serum Hs-CRP and myeloperoxidase. Metabolism. 2012;61(10):1353–60.
43. Tiozzo E, Konefal J, Adwan S, et al. A cross-sectional assessment of metabolic syndrome in HIV-infected people of low socio-economic status receiving antiretroviral therapy. Diabetol Metab Syndr. 2015;7:15. doi:10.1186/s13098-015-0008-5.
44. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43(4):458–66.
45. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21(18):2445–53.
46. Palacios R, Santos J, Gonzalez M, Ruiz J, Marquez M. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS. 2007;18(3):184–7.
47. Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010;24(3):427–35.
48. Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol. 2007;47(12):1570–9.
49. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003.